Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Nanobiotix S.A. (NBTX)

43.99 -2.21 (-4.78%)
As of 10:33:42 AM EDT. Market Open.
Trade NBTX on Coinbase
Chart Range Bar
Loading chart for NBTX
  • Previous Close 46.20
  • Open 43.23
  • Bid 48.03 x 100
  • Ask 52.75 x 100
  • Day's Range 42.79 - 44.24
  • 52 Week Range 3.64 - 57.14
  • Volume 42,853
  • Avg. Volume 76,465
  • Market Cap (intraday) 2.133B
  • Beta (5Y Monthly) 0.58
  • PE Ratio (TTM) --
  • EPS (TTM) -0.58
  • Earnings Date Mar 31, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 34.15

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

www.nanobiotix.com

100

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview: NBTX

Trailing total returns as of 5/20/2026, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .

YTD Return

NBTX
103.00%
CAC 40 (^FCHI)
0.70%

1-Year Return

NBTX
1,015.08%
CAC 40 (^FCHI)
1.89%

3-Year Return

NBTX
846.02%
CAC 40 (^FCHI)
8.01%

5-Year Return

NBTX
183.81%
CAC 40 (^FCHI)
27.57%

Earnings Trends: NBTX

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY21
Revenue --
Earnings --

Q1

FY21

Q2

FY21

Q3

FY21

Q4

FY21

-6M
-4M
-2M
0

Analyst Insights: NBTX

View More

Analyst Price Targets

25.70 Low
34.15 Average
43.99 Current
40.67

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/1/2026
Analyst UBS
Rating Action Maintains
Rating Neutral
Price Action Raises
Price Target 3.5 -> 30

Statistics: NBTX

View More

Valuation Measures

Annual
As of 5/19/2026
  • Market Cap

    2.17B

  • Enterprise Value

    2.22B

  • Trailing P/E

    --

  • Forward P/E

    666.67

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    64.50

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    64.39

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -73.52%

  • Return on Assets (ttm)

    -10.06%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    32.59M

  • Net Income Avi to Common (ttm)

    -23.96M

  • Diluted EPS (ttm)

    -0.58

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    52.75M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -7.89M

Compare To: NBTX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: NBTX

Fair Value

43.99 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: